Hello all
If Gmed and Distributors formalise all MOUs into binding agreements, then the future is as follow:
Primza Distribtors
A) INSIDE CHINA
#1
Beijing Silverlake , China
4.05 million units (~U$405 million to U$615 million) over 5 years
Year Minimum Purchase Quantity:
Year 1 100,000 units (U$10m to $15 million)
Year 2 250,000 units
Year 3 1,000,000 units
Year 4 1,350,000 units
Year 5 1,350,000 units
Total 4,050,000 units
GMV Distribution Agreement for Smartphone Cover in China
09/05/17
https://www.asx.com.au/asxpdf/20170509/pdf/43j49qfmmtw4qt.pdf
B.Sliverlake, website is not available
#2 Shandong Boletong, China
U$65m
430000 to 650000 units,
estimate B2B price at U$100 to U$150 ea
(Unclear if they are for 1,2,3, 4or 5 years?)
https://gmedinnovations.com/asx-announcements/
https://www.asx.com.au/asxpdf/20170727/pdf/43kx57w4gs6g5v.pdf
SDB three hospital/business partners:
Xijing H, Shannxi H, Xiguan H
http://sdboletong.com/index.php?s=/List/index/cid/23.html
How significant are these to SDB business and GMV med-devices?
Beds:
They have a combined >6000 beds for in-patents and surgeries.
vs
Royal Melbourne Hospital has only 570 beds.
How many patients:
They treat >10 million out-pateints in a year, approx the combined population of Sydney/4m, Melbourne/4.5m, Brisbane/2m
How many Primza sensors will they need in future?
B) Primza distributors OUTSIDE CHINA
#3
MEDTL
Cyprus/Greece , U$10.5m
https://www.mymedtl.com
Doctors' testimonials
https://www.mymedtl.com/testimonials
#4
USA, Winolalake , U$10m
http://www.winolalake.com/partners/
Primza
http://www.winolalake.com/software/
GPatch
http://www.winolalake.com/patient-monitoring-and-telemedicine/
#5
India/Taiwan , FCL of UGHL ,
*Yet to be confirmed , re 5/9/18 Asx update *
U$405m , 2.7m units, over 3 years:
Taiwan 0.45m + India 2.25m
= 2.7m units
Y1, U$90m, 600'000 units
Y2, U$135m, 900'000 units
Y3, U$180m, 1200'000 units
Binding MOU for Distribution in India and Taiwan
“UGHL's Tier 1 partners, including Vodafone India, Reliance Communications and BSNL Mobile”
FCL is a subsidiary of UGHL
Subsequent to singing 16/11/17 MOU with GMV , UGHL has moved aggresively expanded into *Aged-care and *Home-care businesses in China, Japan, Thailand.
https://www.otcmarkets.com/stock/UGHL/news
Note:
1.HKSE pre revenue biotech IPO
"To qualify for a Hong Kong listing, biotech candidates must have
a market valuation of at least HK$1.5 billion (US$191.13 million) at the time of listing, one “sophisticated” pre-IPO investor,
a product that has passed a phase one clinical trial primarily aimed at showing its safety, and has regulatory approval to begin phase two to prove its efficacy."
2.Nasdaq IPO
http://venturelawcorp.com/listing-requirements-nasdaq/
https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/
3.For 'watchers and wait-ers' only:
i)ST Share prices catalysts :
posts # 34898808 , 34958919
ii)MT to LT potential re-rating events:
posts #, 35287649 , 34901127 , 35096870 , 34910514
iii)HKSE & Nasdaq
post# 35428139 , 35435633
*Please Dyor before you buy, hold or sell.
Not financial advice.
Aimo.
.
- Forums
- ASX - By Stock
- GMV
- Primza Distributors and MOUs
Primza Distributors and MOUs
-
- There are more pages in this discussion • 527 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online